Novartis Faces More Than Fine In Japan Probe Of Drug-Ad Violations
This article was originally published in PharmAsia News
Executive Summary
Novartis apparently faces more problems in Japan than a requested prosecutorial probe into its allegedly erroneous advertisements for its Diovan (valsartan).